CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group, announced Monday that its subsidiary, Cana Laboratories, has entered into a contract manufacturing agreement with Australia's Humacology, a provider of CBD therapies. Cana will produce up to 500,000 units of Humacology's CBD products, marking the second major contract for Cosmos Health in the past week.
The new partnership follows closely on the heels of Cana's deal with Provident Pharmaceuticals to manufacture 4.32 million units of DE3-SOLE, a vitamin D absorption aid. These consecutive agreements highlight Cosmos Health's focus on expanding its high-margin contract manufacturing business.
Humacology, recently honored with the Cannabiz Award for Innovation, is on a global expansion drive, and CEO James Dale expressed excitement about the partnership with Cana Laboratories. Greg Siokas, CEO of Cosmos Health, indicated that the company is on the verge of finalizing additional profitable manufacturing contracts and will announce further developments as they occur.
Cosmos Health, founded in 2009, has a diverse portfolio of proprietary pharmaceutical and nutraceutical brands and operates a telehealth platform through its acquisition of ZipDoctor, Inc. With a manufacturing facility licensed under European GMP and certified by the European Medicines Agency, Cosmos Health produces a range of healthcare products distributed across Europe, Asia, and North America.
The company's strategic growth includes R&D partnerships targeting major health disorders and the development of novel patented nutraceuticals and complex generics. With offices and distribution centers in Greece and the UK, Cosmos Health continues to broaden its global reach.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.